Latest Breaking News On - Long term safety - Page 2 : vimarsana.com

Novartis atrasentan Phase III data show clinically

Novartis atrasentan Phase III data show clinically
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLambers heerspinkSloan simpsonMichael meoSatoshi sugimotoJonathan grahamImke kappesMarlena abdinoorLoreto mdaBartonm endothelinNicole zinsli sommParag mahantiIsabella zinckNovartis fabhaltaEuropean renal associationExchange commission

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

United statesSloan simpsonNicole zinsli sommLambers heerspinkJonathan grahamSatoshi sugimotoParag mahantiMarlena abdinoorImke kappesIsabella zinckNovartis fabhaltaMichael meoLoreto mdaBartonm endothelinExchange commissionEuropean renal association

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35 1% proteinuria reduction vs placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

United statesCzech republicImke kappesMarlena abdinoorDavid soergelMichael meoSloan simpsonJonathan grahamParag mahantiIsabella zinckMarianne silkjDavid kavanaghNicole zinsli sommSatoshi sugimotoFaculty of medical sciences at newcastle universityGlomerular diseases work group

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandNew yorkIyengars srivathsanLucas boersmaVivek reddyHeart rhythm societyJournal of american medical associationHeart rhythmField ablationBreaking clinical trialsAntonius hospitalLong term safetyMount sinai fuster heart hospitalPulsed fieldThermal ablation

Alkermes plc: Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Alkermes plc: Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew yorkSandy coombsMarisa borgasanoLas vegasAripiprazole lauroxilCraig hopkinsonLaboratory tests for opioid detectionAlkermes incAmerican psychiatric associationInternational society for pharmacoeconomicsPsych congress elevateOutcomes researchAlkermes pharma irelandAmerican society of clinical psychopharmacologyHealthcare resource utilization research offer insights